SPARC and neoplasm: Loss of SPARC in PMN-MDSCs resulted in reduced tumour growth in two subcutaneous breast cancer models and isolation of splenic PMN-MDSCs from wild-type and SPARC−/− mouse spleens demonstrated that those lacking SPARC were unable to suppress T-cell activation [139].